Amarin Corp Plc\Uk
$5.60B- Market cap
- $5.73B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: AMRN stock price at premium vs MKTX $13.63 current versus $3.50 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MKTX's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · MKTX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Capital structure 96% equity / 4% debt · EV / Revenue 6.24x · EV / EBITDA 13.37x
AMRN carries the larger enterprise value at $5.60B against $5.28B; MKTX trades on the lower EV / Revenue multiple (6.24x vs 26.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
MARKETAXESS HOLDINGS INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
0.19x
Net debt / EBITDA
Leverage against operating earnings
3.79x
-1.19x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$690.41M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
Tradeweb Markets Inc.
AMRN vs TW
Virtu Financial, Inc.
AMRN vs VIRT
CME GROUP INC.
AMRN vs CME
FISERV INC
AMRN vs FI
FACTSET RESEARCH SYSTEMS INC
AMRN vs FDS
GLOBAL PAYMENTS INC
AMRN vs GPN
$177.39M
$220.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMRN can reverse revenue decline and sustain a durable move into positive operating margins, then avoid or underweight the stock because the current valuation already implies a large premium relative to MKTX despite weaker profitability and growth.
AMRN’s current price of $16.37 implies a P/S-based value of $2.52, or -84.6% downside, versus the stated MKTX-implied value of $2.49. The stock is also sitting above the top of its historical band, which reinforces that the market is already pricing AMRN far richer than the relative valuation would support.
Supporting Metrics